pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
AstraZeneca projects
4 ClinicalTrials.gov programs sponsored by AstraZeneca.
AstraZeneca has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
D3250C00059
AstraZeneca AB
Severe eosinophilic asthma
1 trial -
D5980C00048
AstraZeneca AB
Chronic Obstructive Pulmonary Disease
1 trial -
D8223C00016
AstraZeneca AB
Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
1 trial -
DS-8201a
AstraZeneca AB
Treatment of patients with HER2-positive breast cancer with or without brain metastasis
1 trial
Frequently asked questions
How many clinical projects does AstraZeneca have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.